TrialThorax2023

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.

Zelalem Temesgen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.